Skip to main content

Advertisement

Table 1 Demographic, genetic, and biochemical data in the total cohort as well as divided into three age tertiles

From: Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations

  Total cohort (n = 716) ≤45 years (n = 237) 46–64 years (n = 242) ≥65 years (n = 237)
Demographic
 Age (years), mean (range) 53.3 (17–99) 29.9 (17–45) 57.3 (46–64) 72.6 (65–99)
 Male, n (%) 305 (42.6) 114 (48.1) 104 (43.0) 87 (36.7)
 Female, n (%) 411 (57.4) 123 (51.9) 138 (57.0) 150 (63.3)
Genetic
APOE ε4–/–, n (%) 506 (70.7) 162 (68.4) 172 (71.1) 172 (72.6)
APOE ε4+/–, n (%) 190 (26.5) 69 (29.1) 64 (26.4) 57 (24.1)
APOE ε4+/+, n (%) 20 (2.8) 6 (2.5) 6 (2.5) 8 (3.4)
Biochemical: CSF Aβ42 (ng/L), mean (SD)
 All genotypes 252.1 (71.0) 251.9 (67.8) 264.9 (67.7) 239.2 (75.2)
APOE ε4–/– 261.2 (70.9) 257.2 (69.5) 274.5 (68.1) 251.8 (73.4)
APOE ε4+/– 234.8 (65.4) 241.4 (64.0) 248.1 (58.3) 211.9 (69.7)
APOE ε4+/+ 185.5 (59.0) 231.3 (51.8) 167.8 (39.1) 164.4 (62.1)
P value* <0.001 0.203 <0.001 <0.001
  1. *P values indicate comparisons of CSF Aβ42 concentrations between the APOE ε4 carrier groups (for the total cohort as well as for each of the tertiles)
  2. APOE apolipoprotein E, Aβ42 beta-amyloid1– 42, CSF cerebrospinal fluid, SD standard deviation